Studies assessing the relationship between dose to the penile bulb (PB) and risk of ED in men treated for prostate cancer with external beam radiation therapy (EBRT) have been critically scored. A review of published literature examining dose received by the PB and clinical erectile function outcomes for patients receiving EBRT was performed. Of 146 retrieved articles, 8 evaluated EBRT-induced ED in relation to PB dose. Half of these articles showed a relationship between dose to PB and ED, and the other half did not. A reliability score (RS) was constructed to more uniformly evaluate strengths and weaknesses of these eight articles. Subsequently, they were scored by two independent reviewers. An average of both scores was calculated. A close consensus was found (identical RS for six of the eight studies; kappa statistic: P ¼ 0.97). The studies with highest RS consistently support a relationship between ED and PB doses, whereas those with low scores did not. The RS-based analysis supports the recommended dose-volume limits specified in the Quantitative Analysis of Normal Tissue Effects in the Clinic review, maintaining the mean dose to 95% of the PB o50 Gy, although the target organ at risk is not likely to be the PB.
INTRODUCTION
Prostate cancer (PC) is among the most prevalent cancers that affect men in Western countries, only surpassed by skin cancer. 1 ED is a frequent side effect of PC treatments that significantly affects quality of life. External beam radiation therapy (EBRT) is favored over other treatment modalities because of its lower risk of impotence, as supported by the Robinson et al.
2,3 meta-analysis. Although the risks of post-radiotherapy ED are well documented, the etiology remains unclear. In normal anatomy, functioning cavernous nerves administer nitric oxide to the penis, resulting in arterial inflow through the internal or accessory pudendal arteries and healthy erectile tissue. This ensures trapping of blood in the penis (venocclusive mechanism) and the achievement of penile erection. 4, 5 As virtually all radiation-induced complications are dose and volume dependent, efforts have been made to determine the nature of the dose-volume relationships for radiation-induced ED in men treated for PC. If a dose-volume response relationship for radiation-induced ED could be identified, it might then be possible for radiotherapy techniques to be optimized to minimize the risk of ED. Unfortunately, there are many differing opinions in the literature for the etiology of radiation-induced ED and the dose-volume effects on penile structures. The Quantitative Analysis of Normal Tissue Effects in the Clinic review performed by Roach et al. 6 addresses the challenges encountered when studying this dose-volume effect, such as the age of the patients, comorbidities and the questionnaires used to evaluate ED.
It is acknowledged that the penile bulb (PB) is not a critical component of the erectile apparatus, but based on several studies it appears that it may be a surrogate for undetermined structures that are critical components of erectile function. Empirical data support this hypothesis. It may be an ideal surrogate because of its proximity to the prostate, as well as the vascular and nerve supply and the high dose portion of the therapy, and it is also easily definable by CT. In addition, animal model studies conducted at the University of California San Francisco and elsewhere demonstrated a PB dose-related response. 7, 8 The purpose of our analysis is to assess the published literature in this area. To this end, a reliability score (RS) was constructed, based on the RS concept used in the Roach and Alexander 9 and Bach et al. 10 papers. This score will be used to evaluate the reliability of each article published on this subject in patients treated with EBRT. Although the findings may also be relevant to patients undergoing brachytherapy, we have chosen to focus this review only on EBRT because of the differences in dose rates, volumes and techniques between these two approaches and the potential impact of the traumatic nature of brachytherapy.
MATERIALS AND METHODS
A thorough journal search was completed via the electronic databases PubMed, Medline, EMBASE and ScIELO on 30 November 2011. The keywords used for the search were combinations of (i) erectile, ED, PB, crura and cavernosa with prostate and (ii) erectile, ED and PB with radiotherapy or radiation. This search yielded 146 articles, of which 14 studies and reviews addressing the issue of the 'relationship between dose to the PB and post EBRT ED' were considered relevant for this critical review. Of these articles, eight reporting ED results in relation to the dose received by the PB after EBRT, with a minimum 2-year follow-up, were analyzed. Impotency after receiving brachytherapy treatment was not reviewed in this paper. Additional literature was reviewed during the development of the RS. This RS (Table 1 ) was based on the Roach and Alexander 9 reliability model. This new score included five items with higher point values attributed to the most relevant criteria. Item 1 is the 'percentage of potent patients before receiving radiation therapy'. This item was graded in a 0-4 scale. In an attempt to standardize pre-and post-treatment potency differences among all patients, our review uses the International Index of Erectile Function (IIEF) scores X20 and Expanded Prostate Cancer Index Composite (EPIC) scores X60, as well as slightly reduced potency or potent on 4-point scales as the potency cutoff values. 11 This was selected as the most important criteria because the higher the percentage of patients who were impotent at baseline the more difficult it would be to assess the impact of EBRT on ED.
Item 2 is the 'potency evaluation' score. This score model was graded in a 0-3 scale. Schroeck et al. 11, 12 found a high correlation between the IIEF and the EPIC scores; thus, after reviewing the literature on potency evaluation scales, these questionnaire tools received the highest point values in our evaluation. The Erection Hardness Score, a 4-point scale, corresponded closely with the IIEF score, as reported by Cappeleri et al., 13 thus-validated questionnaires and 4-grade scores were also considered relevant for this review. Lastly, non-validated questionnaires and potency affirmation were considered least relevant and received the lowest point value. This was selected as the second most important criteria because if the tool for assessing ED was very insensitive, it might make it difficult to assess the impact of EBRT on ED.
Item 3 evaluates the 'dose ranges to the planning treatment volume (PTV)'. Multiple contourers introduce more interobserver variability, and consequently a more variable prescribed bulb dose. A large range of doses prescribed to the PTV (45 Gy difference) would also vary the amount received by the bulb. To consider that ED depends on PB dose response, the bulb must be receiving different doses. This would allow a threshold to be established. This was selected as the third most important criteria because without a wide range of doses and volumes, evidence of a dose-response effect might be difficult to detected because of a narrow range of doses and volumes.
Item 4 registers whether a 'threshold effect' was analyzed in the study. The threshold would be the PB dose after which patients in the study presented ED.
Lastly, Item 5 is the 'PB definition'. Certain trials separately analyzed the corpus spongiosum (PB) from the corpora cavernosa and crura. However, they all separately analyzed ED in relation to the dose to the PB. Considering that the dose this structure received would differ when contoured by different observers, higher points were given to those studies where it was contoured either by a single observer or by consensus. Articles that did not specify how the PB was contoured or where the contouring was inconsistent with the rest of the literature were given a lower score for this item.
Eight articles discussing ED in relation to PB dose after radiotherapy for PC were reviewed independently by two reviewers. The average of both scores was calculated.
RESULTS
There was a very close consensus between the paired reviewer scores with identical RS occurring for six of the eight studies (kappa statistic: P ¼ 0.97). Only 3 items among a total of 40 differed. The average scores obtained for each of the five items of the RS, as well as the summary RS for the eight studies reviewed, are displayed in Table 2 . The RS maximum possible total score was 14. The articles that showed a PB dose-volume relationship consistently scored much higher on average than the other four articles that did not find this relationship (Figure 1 ). These 'positive' articles were Fisch et al., 14 Roach et al., 15 Wernicke et al. 16 and Mangar et al. 17 They all scored very highly on the potency proportion before EBRT, dose ranges, threshold and PB definition items. On the other hand, the four 'negative' articles received higher potency evaluation scores reflecting the method for assessment.
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The Roach et al. 15 , Wernicke et al. 16 , Mangar et al. 17 and van der Wielen et al. 20 papers scored highest in the potency before EBRT category, with 100% of patients included demonstrating potency before treatment.
Brown et al. 19 and Weigner and King 21 used the most rigorous potency evaluation instruments, the IIEF and the EPIC. Dose ranges to the PTV, with multiple observers, were consistently higher in the four articles that found a dosevolume relationship between ED and the PB dose. However, it was also higher in the van der Wielen et al. 20 study. A threshold dose to the PB was found to cause impotence in the four studies that conclude a dose-volume relationship. [14] [15] [16] [17] As for the PB definition, Wernicke et al. 16 and the Selek et al.
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studies defined how it was contoured, however, they did not specify how many researchers outlined it. The Brown et al. 19 and Wiegner and King 21 papers did not explain how the contouring had been done. Lastly, van der Wielen et al. 20 only contoured the PB until both corpora cavernosa did not join together, which is inconsistent with the other studies.
18-21

DISCUSSION
Other studies have recently attempted to address the issue of dose-volume responses to the PB and ED, however, they include results for brachytherapy as well as EBRT. 6, 22, 23 Our analysis evaluates only EBRT and adheres to the necessity of obtaining prospective baseline, as well as long-term follow-up selfadministered ED questionnaires. 6, 22 In addition, all the eight studies included in this analysis have a minimum 2-year follow-up, which has been shown is necessary to adequately quantify the negative impact of radiotherapy. 23 Two of the three differences between reviewers in scoring occurred in the Selek study. The largest discrepancy between reviewers when scoring these articles was in the potency before EBRT score in the Selek et al. 18 study. This was due to the ED evaluation instrument that was used, similar to a 4-grade score. Of the patients considered potent in the study, 43% 'usually presented sufficient erection for intercourse'. Depending on whether this was considered slightly reduced potency or not, there was a 2-point variation in scoring for this item. Although it may be appropriate to categorize ED into five grades of severity, from no ED (IIEF 420) to severe (IIEF 5-7), the average man with ED has an IIEF of p11 (on a scale of up to 25), not zero, as chosen by these authors. The Quantitative Analysis of Normal Tissue Effects in the Clinic review also addresses the evaluation instrument in this paper, and considers that by considering patients with a score '0' as impotent, the baseline level of ED in their study population is underestimated. 6 Had they chosen to include 0 and 1 as indicative of ED, 68% of their patients would have been classified as having developed ED, and consequently preservation of potency would have been based on nine patients. As a result of these issues, it appears that the study by Selek et al. 18 neither proves nor disproves an association between dose of radiation and ED.
In general, the four 'negative' studies found in our analysis were smaller and used different anatomical and chronological definitions of ED. The studies that did not find a relation between the dose-volume to the prostate bulb and ED only scored higher in the potency evaluation instrument item. The difference in relation to the 'positive studies', however, was small, consisting of only 2 points.
The 'negative' Brown et al. 19 study did not treat enough potent patients with high enough doses to the bulb to address the issue of whether more patients would have had ED if their PB would have received a higher dose. The analysis was based on 32 patients treated with intensity-modulated radiation therapy (receiving a mean dose to the PB of 25 Gy). Based on the work reported in the 'positive studies', this is below the threshold in which radiation-induced ED should be expected to occur. Complicating matters further, only 25% of their patients had excellent function before treatment; thus, it is not surprising that baseline function would be the greatest predictor of preserving function.
The van der Wielen et al. 20 'negative study' also fails to make a compelling argument against the dose-response hypothesis. As was mentioned earlier, they defined PB differently than that used in the 'positive studies', making it difficult to comment on dosevolume histogram data-specifically, whether enough of their patients received a high enough dose to increase the risk of radiation-induced impotence. Although their analysis is based on 96 patients, information regarding the use of PDE5 inhibitors was only available for 70 patients. Of these patients, 10% were using PDE5 inhibitors, and there is evidence that the use of these drugs might attenuate the effects of radiation on sexual function. This confusion factor was most probably not present in earlier 'positive studies' because there was no clinical indication of this medication for ED during the treatment of those patients.
The most recent 'negative' study is Wiegner and King. 21 Several problems occur in this study. First, only 62% of the patients included were potent at baseline. Second, the mean EPIC scores at the 50-month follow-up were 20.5 points higher in the subgroup of patients that were potent before treatment, in comparison with the complete sample (n ¼ 32). Also, although patients receiving treatment with ED medications were initially excluded from the study, there was a subgroup that used them during follow-up (25% at last follow-up). There was only a slight difference between the mean EPIC scores of the full sample in comparison with those patients that did not receive treatment with ED medication. Finally, the maximum dose to the PB was an equivalent biological dose when given at 2 Gy per fraction of 25 Gy, as in Brown et al. 19 This was achieved without setting dose constraints to the PB, so as Post-radiotherapy impotence-Assessment E Rivin del Campo et al to avoid compromising dose to the apex of the prostate (with stereotactic body radiation therapy). A threshold analysis was performed for the mean PB dose at the first, median and third quartile, and no significant association with ED was shown; however, this dose does not approach the 50 Gy threshold that the 'positive studies' showed.
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A recent experimental study uses image-guided sterotactic prostate-confined radiotherapy in a rat model. A single 20-Gy fraction (effective biological dose: 92-110 Gy, alpha/beta of 2 and 3 Gy; 2 Gy per fraction) was delivered to the radiotherapy group animals, excluding PB, shaft and testes. The irradiated group showed statistically significant time-dependent ED at 4 weeks. Neuronal nitric oxide synthase was decreased in the cavernous nerve by 4 weeks. In the corpora cavernosa, smooth muscle content was reduced at 9 weeks. This group has also conducted a preliminary dose-response study using 14 and 7 Gy single fractions with the same technique. They report that dosedependent intracavernous pressure decreased at 9 weeks post radiotherapy. 8 The van der Wielen et al. 23 review noted difficulties in consistency between PB dose-volume response studies when defining the PB. Fisch et al.
14 and Roach et al. 15 were considered studies that did not give clear information on how it was contoured. We used the illustrations in these papers to understand their definition of the PB, which coincides with its definition in other papers. The aforementioned study also suggested that if PB sparing was achieved by using a smaller margin around the prostate apex, there would be an oncological risk. We believe that with recent improvements in imaging and radiation treatment techniques, PB dose can be reduced without affecting the PC outcome particularly when image guidance techniques are used.
As we have mentioned above, the Brown et al. 19 study was able to maintain low doses to the PB by using intensity-modulated radiation therapy. This treatment allows a very conformal delivery of radiation therapy to the target volume, with a much lower dose reaching the healthy surrounding tissues. When intensitymodulated radiation therapy is combined with image-guided radiation therapy (IGRT) techniques, there is a much lower risk of geometric miss, with a much better outcome and less adverse effects. The Brown et al. study performed IGRT using abdominal ultrasound. At present, IGRT with daily kilovoltage imaging is preferred. It can also be combined with the implantation of prostatic fiducial markers. This way daily verification of the position of the prostate, as well as of the PB, as delineated in the planning computed tomography scan, can be achieved.
The results of two additional studies have recently been published on dose-volume effects for ED after radiotherapy since we completed this analysis. Both of them support the findings and conclusions of our study. The patients included in these evaluations did not receive hormone therapy and had a minimum follow-up of 2 years after receiving radiation therapy. 24, 25 The first paper prospectively evaluated quality of life in menp60 years old treated with definitive proton therapy for PC. This study by Hoppe et al. 24 scores highly on our RS (RS ¼ 11) because 69% of the patients were potent before treatment, they used the IIEF questionnaire, the PTVs were contoured by multiple observers with large dose ranges to the PTV and they found that a mean dose to the PB X40 cobalt Gy equivalents was related with a larger decline in the sexual summary scores than the s.d. Therefore, they recommend keeping the mean PB dose under 40 cobalt Gy equivalents when possible so as to improve outcomes in sexual function.
The second one studied the correlation between the dose to the PB with ED after three-dimensional conformal radiotherapy. Magli et al. 25 score well on the RS (RS ¼ 10). The main weakness of this study is that only 58% of the patients were fully potent before radiotherapy. On the other hand, the questionnaire used scored very highly (IIEF). The PTV was contoured by multiple physicians, although there was not a wide range of prescribed doses to the PTV. There was a consensus on PB contouring and it was consistent with the other papers. Magli et al. 25 conclude that the patients with ED received a mean dose to the PB of X50 Gy; thus, they propose a threshold to avoid ED between 40 and 45 Gy.
Thus, the results of this reliabilty score coincide with the recommended dose-volume limits specified in the Quantitative Analysis of Normal Tissue Effects in the Clinic review, maintaining the mean dose to 95% of the PB volume to o50 Gy. 6 
CONCLUSION
Considering that essentially all radiation-induced complications are dose and volume dependent, it is virtually certain that radiation-induced ED is associated with a dose of radiation delivered to vessels, nerves, muscles or some combination of these normal structures. 6 The failure of some studies to confirm a dose-volume relationship between the dose of radiation delivered and penile structures may be explained by the methods used to define the anatomy of interest, the definitions of ED used, the number of potent patients before treatment, a higher rate of ED due to treatment-or non-treatment-related factors, chance alone, the use of PDE inhibitors, an insufficient range of doses or the use of lower than threshold doses of radiation.
